These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37016954)

  • 1. Alpha-synuclein in Parkinson's disease: a villain or tragic hero? A critical view of the formation of α-synuclein aggregates induced by dopamine metabolites and viral infection.
    Carmo-Gonçalves P; Coelho-Cerqueira E; de Araujo Lima V; Follmer C
    Expert Rev Neurother; 2023 Apr; 23(4):321-330. PubMed ID: 37016954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    Lima VA; do Nascimento LA; Eliezer D; Follmer C
    ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Carmo-Gonçalves P; Romão L; Follmer C
    ACS Chem Neurosci; 2020 Nov; 11(21):3541-3548. PubMed ID: 33080132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the role of methionine residues on the oligomerization and neurotoxic properties of DOPAL-modified α-synuclein.
    Carmo-Gonçalves P; do Nascimento LA; Cortines JR; Eliezer D; Romão L; Follmer C
    Biochem Biophys Res Commun; 2018 Oct; 505(1):295-301. PubMed ID: 30249394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers.
    Lima VA; Esquinelato R; Carmo-Gonçalves P; Nascimento LAD; Lee H; Eliezer D; Romão L; Follmer C
    FEBS Lett; 2022 Feb; 596(3):309-322. PubMed ID: 34928512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain.
    Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C
    Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
    Svarcbahs R; Julku UH; Myöhänen TT
    J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic effects of human and rodent variants of alpha-synuclein in vivo.
    Landeck N; Buck K; Kirik D
    Eur J Neurosci; 2017 Feb; 45(4):536-547. PubMed ID: 27893183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential direct role of synuclein in dopamine transport and its implications for Parkinson's disease pathogenesis.
    Kim M; Bezprozvanny I
    Biochem Biophys Res Commun; 2023 Sep; 671():18-25. PubMed ID: 37290280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining fibril-induced alpha-synuclein aggregation and 6-hydroxydopamine in a mouse model of Parkinson's disease and the effect of cerebral dopamine neurotrophic factor on the induced neurodegeneration.
    Singh A; Panhelainen A; Reunanen S; Luk KC; Voutilainen MH
    Eur J Neurosci; 2024 Jan; 59(1):132-153. PubMed ID: 38072889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
    Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
    Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain.
    Beatman EL; Massey A; Shives KD; Burrack KS; Chamanian M; Morrison TE; Beckham JD
    J Virol; 2015 Dec; 90(6):2767-82. PubMed ID: 26719256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
    Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
    Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.
    Xiang W; Menges S; Schlachetzki JC; Meixner H; Hoffmann AC; Schlötzer-Schrehardt U; Becker CM; Winkler J; Klucken J
    Mol Neurodegener; 2015 Mar; 10():8. PubMed ID: 25886189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
    Wang W; Nguyen LT; Burlak C; Chegini F; Guo F; Chataway T; Ju S; Fisher OS; Miller DW; Datta D; Wu F; Wu CX; Landeru A; Wells JA; Cookson MR; Boxer MB; Thomas CJ; Gai WP; Ringe D; Petsko GA; Hoang QQ
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9587-92. PubMed ID: 27482083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats.
    Van Den Berge N; Ferreira N; Gram H; Mikkelsen TW; Alstrup AKO; Casadei N; Tsung-Pin P; Riess O; Nyengaard JR; Tamgüney G; Jensen PH; Borghammer P
    Acta Neuropathol; 2019 Oct; 138(4):535-550. PubMed ID: 31254094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-Synuclein and GM1 Ganglioside Co-Localize in Neuronal Cytosol Leading to Inverse Interaction-Relevance to Parkinson's Disease.
    Kumar R; Chowdhury S; Ledeen R
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson's Disease.
    Lindberg I; Shu Z; Lam H; Helwig M; Yucer N; Laperle A; Svendsen CN; Di Monte DA; Maidment NT
    J Parkinsons Dis; 2022; 12(5):1463-1478. PubMed ID: 35527562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
    Sivakumar P; Nagashanmugam KB; Priyatharshni S; Lavanya R; Prabhu N; Ponnusamy S
    Neurochem Int; 2023 Jan; 162():105461. PubMed ID: 36460239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.